Evidence map›Paper›PMID 30214449›Full record

ReviewFrontiers in immunology2018

Regulation of Interleukin-6 Receptor Signaling by TNF Receptor-Associated Factor 2 and 5 During Differentiation of Inflammatory CD4

Hiroyuki Nagashima, Naoto Ishii, Takanori So

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Effect ofAnimal cells and systems · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. [Research advances on the regulation of interleukin-17 signal transduction and the implication of interleukin-17 in sepsis].Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns · 2021
    Review
  13. Article
  14. Roles of TRAFs in Ischemia-Reperfusion Injury.Frontiers in cell and developmental biology · 2020
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiroyuki NagashimaLymphocyte Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States.
Naoto IshiiDepartment of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takanori SoDepartment of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is growing evidence that tumor necrosis factor (TNF) receptor-associated factors (TRAFs) bind to unconventional membrane-bound receptors in many cell types and control their key signaling activity, in both positive and negative ways. TRAFs function in a variety of biological processes in health and disease, and dysregulation of TRAF expression or activity often leads to a patho-physiological outcome. We have identified a novel attribute of TRAF2 and TRAF5 in interleukin-6 (IL-6) receptor signaling in CD4

Indexed as

AnimalsCD4-Positive T-LymphocytesCell DifferentiationCytokine Receptor gp130Encephalomyelitis, Autoimmune, ExperimentalHumansInflammationJanus KinasesMiceReceptors, Interleukin-6Signal TransductionSTAT3 Transcription FactorTh17 CellsTNF Receptor-Associated Factor 2TNF Receptor-Associated Factor 5Cytokine Receptor gp130Janus KinasesReceptors, Interleukin-6STAT3 Transcription FactorTNF Receptor-Associated Factor 2TNF Receptor-Associated Factor 5autoimmunityIL-6inflammationTH17TRAF2TRAF5

Identifiers

PMID30214449
PMCPMC6126464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.